Literature DB >> 23132303

The complexity of prostate cancer: genomic alterations and heterogeneity.

Lara K Boyd1, Xueying Mao, Yong-Jie Lu.   

Abstract

Although prostate cancer is the most common malignancy to affect men in the Western world, the molecular mechanisms underlying its development and progression remain poorly understood. Like all cancers, prostate cancer is a genetic disease that is characterized by multiple genomic alterations, including point mutations, microsatellite variations, and chromosomal alterations such as translocations, insertions, duplications, and deletions. In prostate cancer, but not other carcinomas, these chromosome alterations result in a high frequency of gene fusion events. The development and application of novel high-resolution technologies has significantly accelerated the detection of genomic alterations, revealing the complex nature and heterogeneity of the disease. The clinical heterogeneity of prostate cancer can be partly explained by this underlying genetic heterogeneity, which has been observed between patients from different geographical and ethnic populations, different individuals within these populations, different tumour foci within the same patient, and different cells within the same tumour focus. The highly heterogeneous nature of prostate cancer provides a real challenge for clinical disease management and a detailed understanding of the genetic alterations in all cells, including small subpopulations, would be highly advantageous.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23132303     DOI: 10.1038/nrurol.2012.185

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  229 in total

1.  Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families.

Authors:  Jianfeng Xu; Elizabeth M Gillanders; Sarah D Isaacs; Bao-Li Chang; Kathy E Wiley; S Lilly Zheng; MaryPat Jones; Derek Gildea; Erica Riedesel; Julie Albertus; Diana Freas-Lutz; Carol Markey; Deborah A Meyers; Patrick C Walsh; Jeffrey M Trent; William B Isaacs
Journal:  Prostate       Date:  2003-12-01       Impact factor: 4.104

2.  Novel mutations of epidermal growth factor receptor in localized prostate cancer.

Authors:  Diah A Douglas; Hong Zhong; Jae Y Ro; Carole Oddoux; Aaron D Berger; Matthew R Pincus; Jaya M Satagopan; William L Gerald; Howard I Scher; Peng Lee; Iman Osman
Journal:  Front Biosci       Date:  2006-09-01

3.  Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.

Authors:  Zsofia Kote-Jarai; Ali Amin Al Olama; Graham G Giles; Gianluca Severi; Johanna Schleutker; Maren Weischer; Daniele Campa; Elio Riboli; Tim Key; Henrik Gronberg; David J Hunter; Peter Kraft; Michael J Thun; Sue Ingles; Stephen Chanock; Demetrius Albanes; Richard B Hayes; David E Neal; Freddie C Hamdy; Jenny L Donovan; Paul Pharoah; Fredrick Schumacher; Brian E Henderson; Janet L Stanford; Elaine A Ostrander; Karina Dalsgaard Sorensen; Thilo Dörk; Gerald Andriole; Joanne L Dickinson; Cezary Cybulski; Jan Lubinski; Amanda Spurdle; Judith A Clements; Suzanne Chambers; Joanne Aitken; R A Frank Gardiner; Stephen N Thibodeau; Dan Schaid; Esther M John; Christiane Maier; Walther Vogel; Kathleen A Cooney; Jong Y Park; Lisa Cannon-Albright; Hermann Brenner; Tomonori Habuchi; Hong-Wei Zhang; Yong-Jie Lu; Radka Kaneva; Ken Muir; Sara Benlloch; Daniel A Leongamornlert; Edward J Saunders; Malgorzata Tymrakiewicz; Nadiya Mahmud; Michelle Guy; Lynne T O'Brien; Rosemary A Wilkinson; Amanda L Hall; Emma J Sawyer; Tokhir Dadaev; Jonathan Morrison; David P Dearnaley; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Nicholas Van As; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Colin S Cooper; Aritaya Lophatonanon; Melissa C Southey; John L Hopper; Dallas R English; Tiina Wahlfors; Teuvo L J Tammela; Peter Klarskov; Børge G Nordestgaard; M Andreas Røder; Anne Tybjærg-Hansen; Stig E Bojesen; Ruth Travis; Federico Canzian; Rudolf Kaaks; Fredrik Wiklund; Markus Aly; Sara Lindstrom; W Ryan Diver; Susan Gapstur; Mariana C Stern; Roman Corral; Jarmo Virtamo; Angela Cox; Christopher A Haiman; Loic Le Marchand; Liesel Fitzgerald; Suzanne Kolb; Erika M Kwon; Danielle M Karyadi; Torben Falck Orntoft; Michael Borre; Andreas Meyer; Jürgen Serth; Meredith Yeager; Sonja I Berndt; James R Marthick; Briony Patterson; Dominika Wokolorczyk; Jyotsna Batra; Felicity Lose; Shannon K McDonnell; Amit D Joshi; Ahva Shahabi; Antje E Rinckleb; Ana Ray; Thomas A Sellers; Hui-Yi Lin; Robert A Stephenson; James Farnham; Heiko Muller; Dietrich Rothenbacher; Norihiko Tsuchiya; Shintaro Narita; Guang-Wen Cao; Chavdar Slavov; Vanio Mitev; Douglas F Easton; Rosalind A Eeles
Journal:  Nat Genet       Date:  2011-07-10       Impact factor: 38.330

4.  Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas.

Authors:  Silvia de Muga; Silvia Hernández; Laia Agell; Marta Salido; Nuria Juanpere; Marta Lorenzo; José A Lorente; Sergio Serrano; Josep Lloreta
Journal:  Mod Pathol       Date:  2010-03-05       Impact factor: 7.842

5.  Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics.

Authors:  J Xu
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

6.  FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.

Authors:  Paula Paulo; João D Barros-Silva; Franclim R Ribeiro; João Ramalho-Carvalho; Carmen Jerónimo; Rui Henrique; Guro E Lind; Rolf I Skotheim; Ragnhild A Lothe; Manuel R Teixeira
Journal:  Genes Chromosomes Cancer       Date:  2011-11-12       Impact factor: 5.006

7.  Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization.

Authors:  J Cui; D A Deubler; L R Rohr; X L Zhu; T M Maxwell; J E Changus; A R Brothman
Journal:  Cancer Genet Cytogenet       Date:  1998-11

8.  Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization.

Authors:  J Qian; R B Jenkins; D G Bostwick
Journal:  Urology       Date:  1995-12       Impact factor: 2.649

9.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

10.  Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN.

Authors:  I C Gray; L M Stewart; S M Phillips; J A Hamilton; N E Gray; G J Watson; N K Spurr; D Snary
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

View more
  87 in total

1.  Mouse models for studying prostate cancer bone metastasis.

Authors:  Jinlu Dai; Janine Hensel; Ning Wang; Marianna Kruithof-de Julio; Yusuke Shiozawa
Journal:  Bonekey Rep       Date:  2016-02-17

2.  MicroRNA-144-3p inhibits cell proliferation and induces cell apoptosis in prostate cancer by targeting CEP55.

Authors:  Hao Zheng; Zhenyu Guo; Xiaoqing Zheng; Weijie Cheng; Xing Huang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

3.  Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer.

Authors:  Huawei Cai; Jiu-sheng Wu; Otto Muzik; Jer-Tsong Hsieh; Robert J Lee; Fangyu Peng
Journal:  J Nucl Med       Date:  2014-03-17       Impact factor: 10.057

4.  Development of high resolution 3D hyperpolarized carbon-13 MR molecular imaging techniques.

Authors:  Eugene Milshteyn; Cornelius von Morze; Galen D Reed; Hong Shang; Peter J Shin; Zihan Zhu; Hsin-Yu Chen; Robert Bok; Andrei Goga; John Kurhanewicz; Peder E Z Larson; Daniel B Vigneron
Journal:  Magn Reson Imaging       Date:  2017-01-07       Impact factor: 2.546

5.  Mutational Landscape of Aggressive Prostate Tumors in African American Men.

Authors:  Karla J Lindquist; Pamela L Paris; Thomas J Hoffmann; Niall J Cardin; Rémi Kazma; Joel A Mefford; Jeffrey P Simko; Vy Ngo; Yalei Chen; Albert M Levin; Dhananjay Chitale; Brian T Helfand; William J Catalona; Benjamin A Rybicki; John S Witte
Journal:  Cancer Res       Date:  2016-02-26       Impact factor: 12.701

6.  Differential impact of RB status on E2F1 reprogramming in human cancer.

Authors:  Christopher McNair; Kexin Xu; Amy C Mandigo; Matteo Benelli; Benjamin Leiby; Daniel Rodrigues; Johan Lindberg; Henrik Gronberg; Mateus Crespo; Bram De Laere; Luc Dirix; Tapio Visakorpi; Fugen Li; Felix Y Feng; Johann de Bono; Francesca Demichelis; Mark A Rubin; Myles Brown; Karen E Knudsen
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

7.  Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.

Authors:  Penn Muluhngwi; Abirami Krishna; Stephany L Vittitow; Joshua T Napier; Kirsten M Richardson; Mackenzie Ellis; Justin L Mott; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2016-12-13       Impact factor: 8.679

8.  microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer.

Authors:  Divya Bhagirath; Thao Ly Yang; Nathan Bucay; Kirandeep Sekhon; Shahana Majid; Varahram Shahryari; Rajvir Dahiya; Yuichiro Tanaka; Sharanjot Saini
Journal:  Cancer Res       Date:  2018-02-01       Impact factor: 12.701

9.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

10.  Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.

Authors:  Julius O Nyalwidhe; Lucy R Betesh; Thomas W Powers; E Ellen Jones; Krista Y White; Tanya C Burch; Jasmin Brooks; Megan T Watson; Raymond S Lance; Dean A Troyer; O John Semmes; Anand Mehta; Richard R Drake
Journal:  Proteomics Clin Appl       Date:  2013-09-13       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.